SBIR/STTR Research Award
Novel Alzheimer's Disease Drug Treatment
Award amount
$224,905Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- P2D, INC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- KX3EAX2JEMV8
- Solicitation number
- PA13-234
- Topic code
- NIA
Research abstract
DESCRIPTION (provided by applicant): P2D Bioscience is developing the selective, non-addicting dopamine transport (DAT) inhibitor, PD2XXX, for the symptomatic treatment of Alzheimer's disease (AD). The core symptom of AD is short-term memory impairment. (DSM-IV) In preliminary studies, PD2XXX improved short term memory by over 110% in a well-accepted triple transgenic mouse model of AD (3xTg-AD). 3xTg-AD mice carry mutations of the APP, tau and presenilin 1 genes. Further, 3xTg-AD mice develop the age-dependent plaques and tangles characteristic of AD. Also, 3xTg-AD mice demonstrate the age-dependent cognitive decline observed in Alzheimer's patients. Therefore, our preliminary data indicate that PD2XXX significantly improved short- term memory in an AD model that mirrors the age-dependent development of Alzheimer's neuropathology as well as the cognitive deficits that characterize Alzheimer's clinical pathology. The long term goal of the proposed studies is to develop a safe and effective treatment for
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- A first-in-class orally bioavailable small molecule dual inhibitor targeting NLRP3 and the dopamine transporter to treat AD
- Targeting Latexin for radiation mitigation.
- A first-in-class orally active anti-TNF-alpha inhibitor to treat AD
- A Novel Small Molecule TNF-alpha Inhibitor as a Disease-Modifying Alzheimer's Disease Drug Treatment
- Activated protein C peptides for radio-mitigation
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Evaluate the Safety, Tolerability, and Immunogenicity of Adjuvanted Preventive Dual Aβ/tau Vaccine, Duvax in Healthy Volunteers
- A Drug Discovery Platform to Prioritize Development of Natural Product Neuromodulators for Treating Cognitive Impairment
- VR-CARES: Feasibility of Virtual Reality for Caregiver Assembly, Relief, Empowerment, and Support to improve social connection, health, and at-home dementia care
- Developing an Integrated Brain State Monitor for Personalized Anesthesia Decision Support: Preventing Postoperative Delirium in Elderly and Patients At Risk for Alzheimer's or Related Dementias
- Lead Optimization of a Therapeutic Candidate for Alzheimer’s Disease
Research funding history
52 SBIR/STTR records share this UEI (2001–2021). Reported award amounts total $21,593,440. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services